Penn's innovative Community Health Worker model shows positive results in the outpatient settings for low-income individuals with chronic diseases.
Penn's innovative Community Health Worker (CHW) model has already proven its worth by reducing patient admissions and leading to better health outcomes for hospitalized patients. Now, a recent study by researchers at the Perelman School of Medicine and published in Population Health Management shows that the CHW model can also be used to influence positive changes in outpatient settings, too.
For research purposes, the authors conducted qualitative in-depth interviews with 21 chronically ill, uninsured or Medicaid outpatients from low-income zip codes, and 30 members of their primary care practice staff. With the responses, the researchers created an outpatient manual to administer treatments outside of the hospital setting, hire additional staff, and work with primary care facilities in Philadelphia to implement the CHW model on their premises. The model is called the Individualized Management for Patient-Centered Targets, or simply IMPaCT.
The University of Pennsylvania Health System adopted IMPaCT as part of routine care for over 5000 patients. Recruitment, training, care, and integration systems within the program were established with input from hundreds of patient interviews to address challenges routinely faced.
“IMPaCT has been successfully used for several years throughout the Penn health system,” Shreya Kangovi, MD, MS, executive director of the Penn Center for Community Health Workers and the lead author of the study, said in a statement. “We’ve seen several positive results, including reduced readmission rates and better health outcomes. We wanted to introduce new patients who had not yet been hospitalized to the model, so our study is helping us adapt it to the outpatient setting.”
Under the IMPaCT approach, neighborhood residents are recruited and trained as community health workers. The workers join patients and their providers to set achievable health goals. They also help patients create tailored plans and support patients in achieving those goals. Activities could include exercising with patients at the local YMCA, helping to coordinate doctor's appointments, and providing emotional support through a difficult time. The CHWs link patients with a long-term source of support—like stable primary care or a support group—in order to maintain health gains and prevent future problems.
The model was altered slightly for the outpatient setting on the following themes:
“Our findings are relevant to the growing interest in community health worker programs across the United States,” said Dr Grande, who is also a senior fellow in the Leonard Davis Institute of Health Economics at Penn. “But many payers and provider organizations are tempted to use a trial-and-error approach. This results in a lot of reinventing the wheel, which is costly, time-consuming, and leaves programs open to making common mistakes. Our study describes a way to balance fidelity and fit.”
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More